Kevin Burns
MD CM, FRCPC
Senior Scientist, Inflammation and Chronic Disease
Ottawa Hospital Research Institute
Professor of Medicine, Director
Kidney Research Centre
Bio
Kevin D. Burns, MD, CM, FRCP(C) is Professor of Medicine and past Vice Chair of Research for the Department of Medicine of the Ottawa Hospital and University of Ottawa. He is Senior Scientist and Director of the Kidney Research Centre of the Ottawa Hospital Research Institute, University of Ottawa, and is cross-appointed to the Department of Cellular and Molecular Medicine. Dr. Burns received his B.Sc. and M.D. degrees from McGill University. He completed Internal Medicine Residency and Clinical Nephrology Fellowship training at the University of Ottawa, undertook basic science research training at Vanderbilt University Medical Center, and returned to Ottawa in 1992 as a clinician scientist. Dr. Burns was University and Hospital Division Head of Nephrology from 1997-2005.
Dr. Burns’ research is focused on the function and regulation of the intrarenal renin-angiotensin system in diabetic nephropathy and hypertension, and the pathogenesis and treatment of acute kidney injury. His laboratory has been supported by funds from the Canadian Institutes of Health Research (CIHR), the Kidney Foundation of Canada (KFOC), and the Canada Foundation for Innovation/Ontario Innovation Trust.
Dr. Burns is Past President of the Canadian Society of Nephrology (CSN), and is Chair of the Steering Committee for the KRESCENT Program, a national kidney research training program launched by the CSN, the KFOC, and the CIHR. In 2010, Dr. Burns received the Medal for Research Excellence from the KFOC, in recognition of his contributions to kidney research in Canada.
Research Goals and Interests
News
Publications
miR‐486‐5p Inhibits eNOS and Angiogenesis in Cultured Endothelial Cells by Targeting MAML3
2025-06-01 Go to publicationAutoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARS‐CoV‐2 infection
2025-02-28 Go to publicationmiR-486-5p protects against rat ischemic kidney injury and prevents the transition to chronic kidney disease and vascular dysfunction
2024-05-22 Go to publicationEffects of Two Soluble ACE2-Fc Variants on Blood Pressure and Albuminuria in Hypertensive Mice: Research Letter
2023-01-01 Go to publicationRelated Research at The Ottawa Hospital
- Inflammation and Chronic Disease Program
- Diabetes
- Kidney disease
- Vascular, heart and metabolic disease
- Discovery research
- Molecular and cellular biology
- Regenerative medicine
- Translational research
- Transgenic/knockout models
- Cell therapy
- Disease models
- Gene expression
- Stem cells
- Biomarkers
- Clinical research
- Extracellular vesicles / exosomes